A. Fowler-Taylor

发表

QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study

J. Wedzicha, M. Decramer, J. Ficker, 2013 .

Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study

J. Wedzicha, J. Ficker, P. D’Andrea, 2013 .

Dual Bronchodilation With Once-Daily QVA149 Reduces Exacerbations, Improves Lung Function and Health Status Versus Glycopyrronium and Tiotropium in Severe-to-Very Severe COPD Patients: The SPARK Study

J. Wedzicha, T. Sandström, J. Ficker, 2013 .

QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study

J. Wedzicha, M. Decramer, J. Ficker, 2013 .

Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study

C. Vogelmeier, R. Fogel, K. Chapman, 2016 .

Add-On Omalizumab Significantly Reduces Exacerbation Rates in Children with Inadequately Controlled Moderate–Severe Allergic (IgE-Mediated) Asthma.

H. Fox, H. Milgrom, M. Blogg, 2009, ATS 2009.

Safety of Omalizumab in Children with Inadequately Controlled Moderate–Severe Allergic (IgE-Mediated) Asthma.

H. Fox, H. Milgrom, M. Blogg, 2009, ATS 2009.